Download Files:

Velagliflozin (proline)

$450$1,450

Products Details

Product Description

– Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations[1].

Web ID

– HY-109018A

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– Metabolism-sugar/lipid metabolism

Molecular Formula

– C28H34N2O7

References

– [1]Hoenig M, et al. Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats. J Vet Pharmacol Ther. 2018 Apr;41(2):266-273.|[2]Meier A, et al. The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies. PLoS One. 2018 Sep 13;13(9):e0203655.

CAS Number

– 1539295-26-5

Molecular Weight

– 510.58

Compound Purity

– 99.43

SMILES

– OC([C@@H]1CCCN1)=O.O[C@H]2[C@H](C3=CC(CC4=CC=C(C5CC5)C=C4)=C(C#N)C=C3)O[C@H](CO)[C@@H](O)[C@@H]2O

Clinical Information

– No Development Reported

Research Area

– Metabolic Disease

Solubility

– DMSO : 100 mg/mL (ultrasonic)

Target

– SGLT

Pathway

– Membrane Transporter/Ion Channel

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.